scholarly journals Glycosaminoglycans in therapy of diabetic nephropathy

1996 ◽  
Vol 42 (5) ◽  
pp. 14-18
Author(s):  
A. V. Vorontsov ◽  
I. I. Dedov ◽  
M. V. Shestakova ◽  
T. M. Milenkaya ◽  
A. P. Knyazeva
Keyword(s):  
Diabetic Nephropathy ◽  
Type I Diabetes ◽  
Combined Therapy ◽  
Basal Membrane ◽  
Type I ◽  
Clotting System ◽  
Antiatherogenic Effect ◽  
The Status ◽  
Glomerular Basal Membrane ◽  
Fundus Oculi

Sulodexide, a drug containing glycosaminoglycans, was used in the treatment of patients with type I diabetes. Along with their effects on the blood clotting system, glycosaminoglycans are capable of preventing the mesangial proliferation and hyperproduction of extracellular matrix, as well as thickening of the glomerular basal membrane and impairment of its permeability and charge selection. A reliable antiproteinuric effect of the drug was noted, persisting for 6 weeks after it was discontinued; the excretion of protein with the urine reliably decreased in patients with both, microalbuminuria and proteinuria. Moreover, an antiatherogenic effect (a reliable decrease of serum atherogenicity coefficient) of sulodexide was observed. Assessment of the status of the fundus oculi of diabetics treated with sulodexide demonstrated a positive dynamics during therapy in some of the patients with nonproliferative and preproliferative retinopathy; no deterioration as regards the fundus oculi were noted. Hence, addition of sulodexide to combined therapy of patients with diabetic nephropathy is effective and pathogenetically justified.

scholarly journals Clinical and laboratory characteristics of the renoretinal syndrome in diabetics

1996 ◽  
Vol 42 (3) ◽  
pp. 3-6
Author(s):  
M. I. Balabolkin ◽  
G. G. Mamayeva ◽  
V. Yu. Evgrafov ◽  
L. I. Lyudina ◽  
N. A. Bishele
Keyword(s):  
Diabetic Nephropathy ◽  
Type I Diabetes ◽  
Type I ◽  
Ophthalmological Examination ◽  
Type Ii ◽  
Pathological Changes ◽  
Clinical Methods ◽  
Microcirculatory Disorders ◽  
Lipid Spectrum ◽  
Fundus Oculi

A total of 107 diabetics were examined using general clinical methods, assessment of microalbuminemia, Rehbergs test for renal function, coagulogram, thromboelastogram, lipid spectrum of the serum, and ophthalmological examination. The stages of diabetic nephropathy and retinopathy and degree of the major pathological changes in the retina were found to be in direct correlation. Initial diabetic retinopathy was found to develop earlier than nephropathy in the majority of patients, and preproliferative and proliferative retinopathy was appreciably more incident in the presence of diabetic nephropathy. Changes in the fundus oculi were more expressed in patients with type I diabetes and nephropathy than in those with type II condition. At the same time, the development of diabetic nephropathy was associated with deterioration of the fundus oculi parameters only in diabetics with type II condition, whereas in those with type I disease it influenced only the number of microaneurysms. The progress of diabetic nephropathy with increase of proteinuria may be caused by such risk factors as microcirculatory disorders and changes in the lipid spectrum of the blood serum.

Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes

Diabetes ◽  
1997 ◽  
Vol 46 (2) ◽  
pp. 287-291 ◽  
Author(s):  
A. E. Heesom ◽  
M. L. Hibberd ◽  
A. Millward ◽  
A. G. Demaine
Keyword(s):  
Diabetic Nephropathy ◽  
Aldose Reductase ◽  
Type I Diabetes ◽  
Type I ◽  
Reductase Gene

scholarly journals Experience gained with application of the all-european program “DIABCARE”: summing up the studies and treatment of diabetics in Novosibirsk

1996 ◽  
Vol 42 (2) ◽  
pp. 11-13
Author(s):  
Ye. A. Zhuk ◽  
V. A. Galenok ◽  
N. I. Selezneva ◽  
T. A. Anisimova ◽  
T. A. Mefodyeva
Keyword(s):  
Diabetes Mellitus ◽  
Health Services ◽  
Clinical Features ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
The Status ◽  
European Program ◽  
Set Up

Analysis of clinical features of type I diabetes mellitus and of the status of health services using the chart of Diabcare, an All-European Program, demonstrated that the system of following up such patients is to be altered. The infrastructure of medicare is to be changed, schools are to be set up for training diabetics, diabetological centers organized, patients be provided for with means of automonitoring, and insulin supply be stable.

The natural history of diabetic nephropathy in type I diabetes and the role of metabolic control in its prevention, reversibility and clinical course

1984 ◽  
Vol 21 (1) ◽  
pp. 1-18 ◽  
Author(s):  
Bernardo Léo Wajchenberg ◽  
Emil Sabbaga ◽  
João Américo Fonseca
Keyword(s):  
Diabetic Nephropathy ◽  
Natural History ◽  
Metabolic Control ◽  
Clinical Course ◽  
Type I Diabetes ◽  
Type I ◽  
History Of

A Search for Association between the Polymorphic Markers of PON1 and PON2 Genes and Diabetic Nephropathy in Patients with Type I Diabetes Mellitus

2005 ◽  
Vol 41 (6) ◽  
pp. 688-692
Author(s):  
O. E. Voron’ko ◽  
N. Yu. Yakunina ◽  
M. V. Shestakova ◽  
E. V. Zotova ◽  
L. A. Chugunova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Polymorphic Markers

scholarly journals The C825T polymorphism in the human G-protein β3 subunit gene is not associated with diabetic nephropathy in Type I diabetes mellitus

Diabetologia ◽  
1998 ◽  
Vol 41 (11) ◽  
pp. 1304-1308 ◽  
Author(s):  
D. G. Fogarty ◽  
M. J. Zychma ◽  
L. J. Scott ◽  
J. H. Warram ◽  
A. S. Krolewski
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
G Protein ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Subunit Gene ◽  
C825t Polymorphism

scholarly journals Conjunctival blood flow after endovascular laser therapy in patients with diabetic nephropathy

1997 ◽  
Vol 43 (6) ◽  
pp. 17-20
Author(s):  
Yu. I. Grinshtein ◽  
S. V. Ivliev ◽  
N. B. Osetrova ◽  
S. S. Ilyenkov
Keyword(s):  
Renal Function ◽  
Diabetic Nephropathy ◽  
Renal Insufficiency ◽  
Laser Therapy ◽  
Chronic Renal Insufficiency ◽  
Vascular Tone ◽  
Type I Diabetes ◽  
Type I ◽  
Microcirculatory Disorders ◽  
Reliable Increase

The conjunctival bloodflow was examined in patients with diabetic nephropathy with different status of renal function and changes in the microcirculatory bed assessed after endovascular laser therapy. Twenty-five donors and twenty-one patients with medium-severe and grave type I diabetes complicated by diabetic nephropathy were followed up. Microcirculatory disorders in the eyeball conjunctiva progressed as renal function deteriorated, which was evident from a reliable increase of the total conjunctival index in parallel with the progress of chronic- renal insufficiency. A course of endovascular laser therapy reliably improved the microcirculation: the arterio-venular coefficient increased and the total conjunctival index decreased in patients with latent and conservatively curable stages of chronic renal insufficiency due to normalization of vascular tone, boosting of the bloodflow, and decrease of red cell sludging.

scholarly journals Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in Type I diabetes mellitus

Diabetologia ◽  
2000 ◽  
Vol 43 (12) ◽  
pp. 1540-1543 ◽  
Author(s):  
S. Araki ◽  
Y. Makita ◽  
L. Canani ◽  
D. Ng ◽  
J. H. Warram ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Paraoxonase 1 ◽  
Type I

T-activin in combined therapy of type I diabetes mellitus

2019 ◽  
Vol 43 (3) ◽  
pp. 23-25
Author(s):  
V. I. Novikov ◽  
V. A. Shostak
Keyword(s):  
Time Course ◽  
Type I Diabetes ◽  
Combined Therapy ◽  
Insulin Dose ◽  
Type I ◽  
T Helper ◽  
Daily Insulin ◽  
Immune Parameters ◽  
Daily Insulin Dose

The effects of t-activin on the time course of immunohormonal, metabolic, and clinical parameters were studied in patients with newly diagnosed type I diabetes (n = 50, aged 17 to 35, followed up for 2 years; controls: 20 patients with type 1 disease treated traditionally). An appreciable decrease of basal and stimulated levels of C-peptide, shifted T-helper to T-supprcssor ratio caused by a decrease of T-suppressor level, and an increase of the immunoregulatory index were observed at the debut of type 1 diabetes; these shifts gave grounds sufficient to prescribe t-activin. Tactivin therapy for 2 years led to a decrease of the T-helper/T-suppressor imbalance due to an increase of the T-suppressor content, normalization of IRI, increase of the basal and stimulated C-peptidc levels, normalization of HbAlc at a daily insulin dose of 0.4 U/kg, and a stable course of the disease. In the controls the immune parameters and hormones did not normalize, daily insulin dose was 0.6 U/kg, and the disease course unstable. Hence, t-activin not only corrected the immunity, but metabolism as well, which resulted in stimulation of repair regeneration of pancreatic p-cells.

Sign in / Sign up

Export Citation Format

Share Document